What is Cytokinetics's other commercial liabilities?

Cytokinetics (CYTK) reported other commercial liabilities of $68.86M in Q1 2026.

How has Cytokinetics's other commercial liabilities changed year-over-year?

Cytokinetics's other commercial liabilities increased by 58.8% year-over-year, from $43.36M to $68.86M.

What is the long-term trend for Cytokinetics's other commercial liabilities?

Over 5 years (2020 to 2025), Cytokinetics's other commercial liabilities has grown at a 33.9% compound annual growth rate (CAGR), from $19.32M to $83.28M.

Cytokinetics CYTK Other Commercial Liabilities

Other Commercial Liabilities at other companies

Corcept TherapeuticsCORT

——

Boston ScientificBSX

——

Other financials

Income statement

See full

Revenue$19.4M+1,126%

Operating income-$183.6M-18.0%

Net income-$206.0M-27.7%

EPS (diluted)-$1.67-22.8%

Balance sheet

See full

Cash & equivalents$129.8M+76.2%

Total debt$418.2M+75.8%

Total equity-$826.6M-210%

Total assets$1.3B+0.7%

Cash flow

See full

Operating cash flow-$145.5M-10.5%

CapEx$5.9M+4.7%

Free cash flow-$151.4M-10.3%

Valuation

See full

Market cap$10.7B+70.6%

Enterprise value$10.98B+70.7%

P/S101.1×-225×

Profitability

See full

Operating margin-605.1%-268pp

Net margin-784%-337pp

FCF margin-518.8%-223pp

Returns & leverage

See full

Return on equity-337.6%—

Debt / equity2.2×—

Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cytokinetics's other commercial liabilities?: Cytokinetics (CYTK) reported other commercial liabilities of $68.86M in Q1 2026.
How has Cytokinetics's other commercial liabilities changed year-over-year?: Cytokinetics's other commercial liabilities increased by 58.8% year-over-year, from $43.36M to $68.86M.
What is the long-term trend for Cytokinetics's other commercial liabilities?: Over 5 years (2020 to 2025), Cytokinetics's other commercial liabilities has grown at a 33.9% compound annual growth rate (CAGR), from $19.32M to $83.28M.